Jacques Thélu, the Flogentec patent holder, is a research manager for the French national research agency (CNRS).
He has a Doctorate in Biochemistry (the bacterial oxidization of short-chain polyoxyethylenes ) as well as a PHD in Natural Science (specialty : the purification and characterization of exoantigens of Plasmodium falciparum obtained in vitro).
He is an expert in several wide-ranging domains including : developmental biology, molecular biology, protein biology, micro-surgery, the transplant of modified cells by transfection, progenital skin cells, molecular signals and in situ hybridization.
Dr Thélu has also acquired a wide range of industrial experience in the fields of automatisation and biotechnology with several blue chip organizations. He has filed and obtained patents for several innovative technologies including :
• A patented process outlining the procedure for vaccine production
• An innovative process for the automated production of P falciparum cell culture.
• A patent covering an innovative immunological test.
Links :
ABOUT US
Flogentec is a Business Unit of Floralis, the subsidiary of University Joseph Fourier (UJF), Grenoble, France. Floralis is a private company and the technology transfer arm of the UJF which is one of France's most successful universities in terms of patent development. An SAS developed with a start-up capital of 1,5m €, in 2004, the company is responsible for managing the intellectual property and the transfer of technology from UJFs laboratories to the market place through a variety of means including Business Unit development, licensing and company creation.
Floralis manages a portfolio of 140 patent families and works in a wide variety of scientific fields including bioscience, health science, chemistry, physical science, engineering and computer science.